Compare TARA & OPP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | TARA | OPP |
|---|---|---|
| Founded | N/A | 2010 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Finance/Investors Services |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 165.5M | 197.7M |
| IPO Year | N/A | N/A |
| Metric | TARA | OPP |
|---|---|---|
| Price | $5.69 | $7.87 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 6 | 0 |
| Target Price | ★ $20.40 | N/A |
| AVG Volume (30 Days) | ★ 815.8K | 108.0K |
| Earning Date | 11-10-2025 | 01-01-0001 |
| Dividend Yield | N/A | ★ 14.41% |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $2.77 | $7.26 |
| 52 Week High | $7.82 | $8.83 |
| Indicator | TARA | OPP |
|---|---|---|
| Relative Strength Index (RSI) | 50.75 | 42.27 |
| Support Level | $5.03 | $7.83 |
| Resistance Level | $5.80 | $8.01 |
| Average True Range (ATR) | 0.30 | 0.07 |
| MACD | 0.00 | 0.02 |
| Stochastic Oscillator | 67.86 | 31.82 |
Protara Therapeutics Inc is committed to identifying and advancing transformative therapies for people with cancer and rare diseases. The company discovers, develops and delivers breakthrough therapies to people who have limited treatment options. Its portfolio includes its program, TARA-002, being developed for the treatment of lymphatic malformations, and intravenous (IV) choline chloride, a phospholipid substrate replacement therapy for the treatment of intestinal failure associated liver disease (IFALD).
RiverNorth/DoubleLine Strategic Opportunity Fund Inc is a closed-end management investment company. The company's investment objective is to seek current income and overall total return.